



5 Masterclass in Lung Cancer

22 23 & 24

JULY, 2022



**Hotel Courtyard
Marriott, Mumbai**

Patrons

Dr. S H Advani, Mumbai
Dr. Rajesh Mistry, Mumbai
Dr. V Kannan, Mumbai

Organizing Secretary

Dr. Ashay Karpe, Mumbai **Dr. Anil Tibdewal, Mumbai**
Dr. Prashant Chhajed, Mumbai **Dr. Priya Eshpuniyani, Mumbai**
Dr. Vijay Patil, Mumbai

Chairman Scientific Committee

Dr. Kumar Prabhash, Mumbai **Dr. Vanita Noronha, Mumbai**

Scientific Committee

Dr. Ramakant Deshpande, Mumbai
Dr. Navneet Singh, Chandigarh
Dr. Bharat Bhosale, Mumbai

Dr. Nandini Menon, Mumbai
Dr. Trinanjan Basu, Mumbai
Dr. Vikas Talreja, Kanpur

Dr. Akhil Kapoor, Varanasi
Dr. Ajay Singh, Mumbai
Dr. Avinash Talele, Mumbai



Registration Link

<https://webinar365.in/hcmpl-lungmasterclass/>



contact@cancerresearchfoundation.in

Organizing Committee

Patrons



Dr. S H Advani
Mumbai



Dr. Rajesh Mistry
Mumbai



Dr. V Kannan
Mumbai

Organizing Secretary



Dr. Ashay Karpe
Mumbai



Dr. Prashant Chhajed
Mumbai



Dr. Vijay Patil
Mumbai



Dr. Prriya Eshpuniyani
Mumbai



Dr. Anil Tibdewal
Mumbai

Chairman Scientific Committee



Dr. Kumar Prabhash
Mumbai



Dr. Vanita Noronha
Mumbai



Organizing Committee

Scientific Committee



Dr. Ramakant Deshpande
Mumbai



Dr. Navneet Singh
Chandigarh



Dr. Bharat Bhosale
Mumbai



Dr. Nandini Menon
Mumbai



Dr. Trinanjan Basu
Mumbai



Dr. Vikas Talreja
Kanpur



Dr. Akhil Kapoor
Varanasi



Dr. Ajaykumar Singh
Mumbai



Dr. Avinash Talele
Mumbai



Early Lung Cancer
Stage IV Non Driver Mutated PDL1 Positive
Day 1- 22nd July || 10:00-07:00pm

Time	Topic	Objective	Speaker
10:00-10:05AM	Welcome & Introduction		Dr Prriya Eshpuniyani Consultant Thoracic Surgeon, Department Of Surgical Oncology Asian Cancer Institute, Mumbai
Screening:			
10:05-10:20AM	Screening & Prevention For Lung CA	Indications- Whom To Screen, When To Screen, How To Screen, Why To Screen, Postscreening How To Confirm Lung CA, Adverse Events Of Screening	Dr Gautam Panda Consultant Medical Oncologist Tata Memorial Hospital, Mumbai
Preoperative Evaluation:			
10:20-10:35AM	Preop Evaluation For Surgical Fitness Of Surgery In Early Stage Lung Cancer	Lung Fitness, Cardiac Fitness, Other W/U	Dr Prriya Eshpuniyani Consultant Thoracic Surgeon, Department Of Surgical Oncology Asian Cancer Institute, Mumbai
10:35-10:50AM	Mediastinal Evaluation For Early Stage Lung CA	Indications- Whom, When, How, Why, Adverse Events Of Screening	Dr Devayani Niyogi Consultant Thoracic Surgeon, Tata Memorial Hospital Mumbai
10:50-11:05AM	Evaluation Of Early Stage Lung Cancer - Role Of PET Scan	Whom To Do, Type, Why, Interpretation, Limitations	Dr Nilendu Purandare Associate Professor & Consultant Radiologist Tata Memorial Hospital, Mumbai
11:05-11:20AM	Evaluation Early Stage CA Lung- Role Of MRI Brain	Whom, Type, Why, Interpretation, Limitations	Dr. Nivedita Chakrabarty Assistant Professor, Dept. of Radiology Tata Memorial Hospital, Mumbai



Time	Topic	Objective	Speaker
11:20-12:05PM	Panel Discussion: Lung Carcinoid		
	Moderator		Dr Ameya Puranik Assistant Professor Nuclear Medicine Tata Memorial Hospital, Mumbai
	Panelists:		
	Dr Devayani Niyogi Consultant Thoracic Surgeon, Tata Memorial Hospital Mumbai	Dr Vijay Patil Professor (Medical Oncology) Solid Tumor, Tata Memorial Centre, Mumbai	
	Dr Nilendu Purandare Associate Professor & Consultant Radiologist Tata Memorial Hospital, Mumbai	Dr Nupur Karnik Assistant Professor , Department of Pathology , Tata Memorial Centre, Mumbai	
	Dr Indraja Dev Assistant Professor Nuclear Medicine Tata Memorial Hospital, Mumbai		
Management Of Early Stage Lung CA:			
12:05-12:20PM	Surgery - Early Stage Lung Cancer	Why Surgery, Which Type- VATS Vs Open, What Is Adequate For Local Tumor, What Is Adequate For Nodal Tumor, Post Op- Morbidity/ Complications/ Mortality, Results Of Only Surgery	Dr. Virendra Tiwari Assistant Professor Thoracic Oncology Tata Memorial Hospital, Mumbai
12:20-12:35PM	SBRT- Early Stage Lung Cancer	Indications, Type, Dose, Time And Fractionation, Response Evaluation, Results, Complications	Dr Anil Tibdewal Assistant Professor Radiation Oncology Tata Memorial Centre, Mumbai
12:35-12:50PM	Early Stage Lung Cancer - Adjuvant Chemotherapy	Indication, Regimen,Cycle,Tolerance, Long Term Effects	Dr Suhas Aagre Consultant Medical Oncologist and Hemato-Oncologist Asian Cancer Institute, Mumbai
Session Sponsored By: 			
12:50-01:05PM	Adjuvant Targeted Therapy In EGFR Mutated Early Stage Lung Cancer	Indication, TKI Which?, How Long?, Results, Complications	Dr Ajay Singh Consultant Medical Oncologist Tata Memorial Centre, Mumbai




Time	Topic	Objective	Speaker
01:05-01:20PM	Follow Up After Treatment Completion In Early Stage Lung Cancer	How Frequent, What Modalities, Tackling Chronic Complications	Dr Anup Toshniwal Assistant Professor Department of Medical Oncology Asian Hospital, Aurangabad
01:20-02:20PM	Case Based Viva 15 Min - History/Physical Examination 15 Min - Investigations 30 Min - Selection Of Treatment & Follow Up		
	Moderator:	Dr Vamshi Krishna Director, Medical Oncology and Hematology Institute of Oncology AIG Hospitals, Hyderabad	
	Examiners:		
	Dr George Karimundackal Professor, Thoracic Surgery Tata Memorial Hospital, Mumbai	Dr Sanjay Sharma, Senior Consultant Surgical Oncologist Director Asian Cancer Institute, Mumbai	
	Dr Bhavesh Parikh Head Ahmedabad Cluster Shalby Hospital Ahmedabad	Dr. Naveen Mummudi Associate Professor, Department of Radiation Oncology Tata Memorial Centre, HBNI University, Mumbai	
	Dr Unnati Desai Associate Professor, Pulmonologist Nair Hospital, Mumbai	Dr Sagar Gayakwad Senior Consultant, Radiation Oncologist Asian Hospital, Mumbai	
	Dr Mehl Thakkar Consultant Pulmonologist, Jupiter Hospital, Mumbai		
	Presenters:		
	Dr Prashant Nayak Radiation Oncologist	Dr Unmesh Mukherjee Radiation Oncologist	
	Dr Atul Medical Oncologist	Dr Karthik Surgical Oncologist	
	Dr Sreedharan Surgical Oncologist		
02:20-03:00PM	LUNCH		



<i>Time</i>	<i>Topic</i>	<i>Objective</i>	<i>Speaker</i>
Immunotherapy: Stage 4 Non Driver Mutated PDL1 Positive			
03:00-03:15PM	Interpretation Of PD1 1 MSI TMB In NSCLC	Which Antibody, How To Score, How To Interpret	Dr Rajiv Kumar Kaushal Associate Professor Department of Pathology Tata Memorial Hospital Mumbai
03:15-03:30PM	Selection Of 1st Line Immunotherapy Pdl1 > 50% & 1% In NSCLC	Regimen, Schedule, Adverse Event And Compliance, Efficacy	Dr Navneet Singh Additional Professor, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh
03:30-03:45PM	Selection Of 1st Line Immunotherapy In PDL1 Negative & Non Driver Mutations	Regimen, Schedule, Adverse Event And Compliance, Efficacy	Dr Manu Prasad Associate Professor Department Of Clinical Hematology and Medical Oncology Malabar Cancer Centre, Thalassery Kerala
03:45-04:00PM	Biomarkers For Predicting Efficacy Of IO (Non PDL1 NON MSI NON TMB)	Which Biomarkers Apart From PDL1/TMB/MSI, How Robust, How To Do Them	Dr Prabhat Malik Associate Professor, Department of Medical Oncology All India Institute of Medical Sciences, Delhi
04:00-04:15PM	Use Of Immunotherapy In Patients With Poor Performance Status	Regimen, Schedule, Adverse Event And Compliance, Efficacy	Dr Kshitij Joshi Consultant, Medical Oncologist Mumbai Oncocare Centre, Mumbai
04:15-04:30PM	Use Of IO In Driver Mutated Patients	Regimen, Schedule, Adverse Event And Compliance, Efficacy	Dr Hollis Dsouza Director, Medical Oncology Grace Oncology Mumbai
04:30-04:45PM	Mechanism Of Resistance On IO	Pathways That Suggest Primary Resistance And Secondary Resistance	Dr Gunjesh Singh Consultant, Medical Oncology, Bhagwan Mahavir Medical Superspeciality Hospital, Ranchi



Time	Topic	Objective	Speaker
04:45-05:00PM	Therapy Post Progression On IO + Chemotherapy	Regimen, Schedule, Adverse Event And Compliance, Efficacy	Dr Amol Patel Professor, Medical Oncology, INHS Asvini, Mumbai
05:00-06:00PM	"Case Based Viva- 15 Min - History/Physical Examination 15 Min- Investigations 30 Min- Management"		
Moderator:		Dr Govind Babu Kanakasetty Consultant Medical Oncologist, HCG Hospitals, Bangalore	
Examiners:			
Dr Kumar Prabhash Prof. & Head- Department of Medical Oncology Tata Memorial Hospital Parel, Mumbai		Dr Shekhar Patil Senior Consultant, Medical Oncologist HCG, Bengauru	
Dr Amit Joshi Professor, Department of Medical Oncology Tata Memorial Hospital, Mumbai		Dr Sharmila Aggarwal Senior Radiation Oncologist Jaslok Hospital, Mumbai	
Dr Ketaki Utpat Consultant, Pulmonologist Nair Hospital, Mumbai			
Presenters:			
Dr Deep Vora		Dr Mounika Y	
Dr Sayak			
06:00-06:15PM	Neoadjuvant Immunotherapy In Early Stage Lung Cancer		Dr Sewanti Limaye Consultant, Medical Oncology Director Clinical and Translational Oncology Research, HN Reliance Hospital Mumbai
06:15-06:45PM	Pharma Session 1		TBC
Session Sponsored By:			
06:45-07:15PM	Redefining Survival Expectations in NSCLC_Keynote_189_and_Keynote_407		Dr Pushpak Chirmade Consultant Medical Oncologis Oncura Hematology and Oncology Care Mumbai
Session Sponsored By:			
07:15-07:45PM	Choosing Right VAD In Lung Cancer Patients		TBC
07:30PM Onwards	Closing Remarks Followed By Dinner		Dr Prriya Eshpuniyani Consultant Thoracic Surgeon, Department Of Surgical Oncology Asian Cancer Institute, Mumbai



Day 2- 23rd July
10:00-07:00pm

Time	Topic	Objective	Speaker
10:00-10:05AM	Welcome & Introduction		Dr Ashay Karpe Consultant Medical Oncology S L Raheja (A Fortis Associate) Hospital Mahim, Mumba
Locally Advanced Lung Cancer:			
10:05-10:20AM	Chemotherapy In Locally Advanced Lung CA- NACT / Adjuvant	Indications, Regimen Selections, Response Rates, Complications, Compliance, Benefit, Adjuvant Vs NACT	Dr Rushabh Kothari Consultant Medical Oncologist Can Cure Cancer Centre Narayana Multispeciality Hospital, Ahmedabad
10:20-10:35AM	Surgery After NACT In Locally Advanced Lung CA	How Many Are Operable After NACT, Benefit Of Surgery, Complications, During NACT Lung Rehabilitation- Surgeon's View	Dr Sabita Jivnani Professor, Thoracic Surgery Department Of Surgical Oncology Convener, Thoracic Disease Management Group Member, Institutional Ethics Committee Tata Memorial Hospital, Mumbai
10:35-10:50AM	Radiation In LALC	Selection Of Patient, Time, Dose And Fractionation, Radiation Volumes, Organ At Risk Constraints, Results- Efficacy, Complications	Dr Anil Tibdewal Assistant Professor Radiation Oncology Tata Memorial Centre, Mumbai
10:50-11:05AM	Concurrent Chemotherapy	Regimen Selection, Results Efficacy, Complications, Compliance	Dr Amit Agrawal Assistant professor, Dept of Medical Oncology AIIMS, Raipur
Session Sponsored By: 			
11:05-11:20AM	Maintenance Therapy In Locally Advanced Stage III NSCLC - Durvalumab	Regimen, Schedule, Adverse Event And Compliance, Efficacy	Dr Srinivas KG Senior Consultant Medical Oncologist HCG, Mysore



Time	Topic	Objective	Speaker
------	-------	-----------	---------

11:20-11:50AM

Debate: Systemic Therapy Sequencing
In Early Stage Resectable Lung Cancer

Neo Adjuvant

Dr Kripa Bajaj
Consultant,
Medical
Oncologist
Basavatarakam
Indo American
Cancer Hospital &
Research
Institute,
Hyderabad

Vs

Adjuvant

Dr Mridul
Malhotra
Senior Consultant,
Medical Oncology
Paras Healthcare
Pvt. Ltd
Gurugram

11:50-01:00PM

Case For VIVA - NSCLC-Locally
15 Min - History/Physical Examination
15 Min- Investigations
30 min- Selection of therapy
(RT versus Sx, NACT versus ACT,
Role IO)

Moderator:

Dr Nikhil Kalyani
Consultant
Radiation Oncologist
Jaslok Hospital, Mumbai

Examiners:

Dr Tanweer Shahid,
Head of Department & Head of
Academics & Research
Department of Radiation
Oncology Apollo
Multispeciality
Hospital, Kolkata

Dr Moses Arunsingh
Consultant Clinical Oncologist,
Tata Medical Center, Kolkata

Dr Purvish Parikh
Precision & Medical Oncologist,
Asian Institute of Oncology,
Somaiya Hospital, Mumbai

Dr Ramakant Deshpande
Executive Chairman
Somaiya Ayurvihar - Asian Cancer
Institute, Mumbai

Dr Saravana R
Thoracic Surgical Oncologist
Thangam Cancer Center, Namakkal

Dr Vishwanath Pujari
Associate Professor
JJ Hospital, Mumbai

Presenters:

Dr Pradnya Chopade

Dr Sreenivas Gopinath

Dr Arnav T



Time	Topic	Objective	Speaker
------	-------	-----------	---------

EGFR Mutated Lung Cancer

01:00-01:15PM	Interpretation Of NGS What A Clinician Should Know	RT-PCR, NGS, IHC	Dr Anuradha Choughule Professor & Scientist Incharge Medical Oncology Molecular Laboratory Tata Memorial Hospital, Mumbai
---------------	--	------------------	--

Session Sponsored By: AstraZeneca

01:15-01:30PM	Osimertinib Or Decotinib As First Line Therapy In EGFR Mutated Lung Cancer	Efficacy, Side Effects, Tips For Selection Of Patient	Dr Mansi Sharma Consultant Medical Oncology Rajiv Gandhi Cancer Institute and Research Centre, Delhi
---------------	--	---	---

01:30-01:45PM	First Line- TKI + Something In EGFR Mutated Lung Cancer	Patterns- Chemotherapy/ Bev/ Metformin, Pros Over Third Generation TKI, Efficacy, Side Effects, Tips For Selection Of Patient	Dr Akhil Kapoor Assistant Professor, Medical Oncology Tata Memorial Hospital (HBCH & MPMMCC), Varanasi
---------------	---	---	---

01:45-02:00PM	Mechanism Of Resistance To Osimertinib In EGFR Mutated Lung Cancer	Mechanism Of Resistance, Pathways , Mutations, Small Cell Transformation	Dr Chakor Vora Consultant - Medical Oncology and Hematology Sassoon Hospital, Pune
---------------	--	--	---

02:00-02:30PM LUNCH

Session Sponsored By: AstraZeneca

02:30-02:45PM	Post Osimertinib Options In EGFR Mutated Lung Cancer	Agents, Efficacy, Side Effects And Tips For Selection	TBC
---------------	--	---	------------



<i>Time</i>	<i>Topic</i>	<i>Objective</i>	<i>Speaker</i>
02:45-03:45PM	Case Base VIVA- Driver Mutated NSCLC 15 Min - History/Physical Examination 15 Min- Investigations 30 Min- Management		
	Moderator-	Dr Anu Rajpurohit Consultant Medical Oncologist SMS Hospital, Jaipur	
	Examiners:		
	Dr Nikhil Ghadyalpatil Consultant Medical Oncologist Yashoda Cancer Institute, Hyderabad	Dr. Aseem Samar Consultant Medical Oncology Bhagwan Mahaveer Cancer Hospital & Research Center, Jaipur	
	Dr Ashish Bakshi Consultant Medical Oncologist LH Hiranandani Hospital, Fortis Hospital Jupiter Hospital, Mumbai	Dr B K Smruti Consultant, Medical Oncologist Lilavati & Bombay Hospital , Mumbai	
	Dr Tarachand Gupta Consultant Medical Oncologist, Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur	Dr Bhavin Visariya, Radiation Oncologist, HCG ICS Khubchandani Cancer Centre, Mumbai	
	Presenters:		
	Dr Venkatesh K (Medical Oncologist)	Dr Harsh Sahu (Medical Oncologist)	
	Dr Gargee Mulaye (Radiation Oncologist)		



<i>Time</i>	<i>Topic</i>	<i>Objective</i>	<i>Speaker</i>
03:45-04:00PM	Interpretation Of ALK	Fish IHC NGS	Dr Pratik Chandrani Scientific Officer - D, Medical Oncology Department, TMH Computational Biology Centre, ACTREC Mumbai
04:00-04:15PM	Selection Of 1st Line Therapy -1st Or 2nd Generation ALK Inhibitors In ALK Rearranged NSCLC	Agents, Efficacy, Side Effects And Tips For Selection	Dr Naresh Somani Director Oncology & HOD Medical Oncology HCG Cancer Center, Jaipur
04:15-04:30PM	Molecular Resistance Mechanism Of ALK Inhibitors	Mechanism Of Resistance , Pathway Mutation And How To Deduct Them	Dr Nandini Menon Assistant Professor Medical Oncology Tata Memorial Hospital, Mumbai
04:30-04:45PM	Selection Of Agent Post 2nd And 3rd Generation ALK Inhibitors Resistance	Agents, Efficacy, Side Effects And Tips For Selection	Dr Bharat Bhosale Consultant Medical Oncologist Bombay Hospital, Mumbai

MET

04:45-05:00PM	Interpretation Of MET Amplification On EXON 14 Skip Mutation In NSCLC	FISH, IHC, NGS	Dr Vidya Veldore, Clinical Director 4baseCare Onco solutions Pvt Ltd. Bangalore
05:00-05:15PM	Selection Of 1st Line Therapy For MET Amplification And MET EXON 14 Mutation In NSCLC	Agents, Efficacy, Side Effects And Tips For Selection	Dr Siddharth Turkar Director Radiant Superspeciality and Cancer Hospital, Raipur
05:15-05:30PM	Mechanism Of Resistance To MET TKI And Therapy Post Resistance IN NSCLC	Agents, Efficacy, Side Effects And Tips For Selection	Dr Sudeep Das Consultant Medical oncology and Hemato oncology at Medica Superspeciality Hospital, Kolkata

ROS

05:30-05:45PM	Interpretation Of ROS 1 Rearrangement In NSCLC	FISH, IHC, NGS	Dr Sunil Pasricha Senior Consultant, Oncopathology Rajiv Gandhi Cancer Institute And Research Centre, Delhi
---------------	--	----------------	---



Time	Topic	Objective	Speaker
------	-------	-----------	---------

05:45-06:00PM	Selection Of 1st Line Therapy For ROS 1 Rearrangement IN NSCLC	Agents, Efficacy, Side Effects And Tips For Selection	Dr Venkata Pradeep Babu Senior Consultant Medical Oncology, Assam Cancer Care Foundation, Assam
---------------	--	---	---

06:00-06:15PM	Mechanism Of Resistance To ROS 1and Therapy Post Resistance In NSCLC	Agents, Efficacy, Side Effects And Tips For Selection	Dr Raajit Chaana Consultant Medical Oncology Dharamshila Narayana Superspecialty Hospital, Delhi
---------------	--	---	--

Session Sponsored By:



06:15-06:45PM	IO Combinations In First Line NSCLC _ Exploring New Treatment Avenues		Dr Alok Goel, Consultant Medica Oncologist Homi Bhabha Cancer Hospital, Sangrur
---------------	---	--	---

Session Sponsored By:



Chairperson

Dr S H Advani
Director,
Department of
Oncology
Jaslok Hospital,
Mumbai

06:45-07:15PM	Case Based Discussion: Optimal Sequencing of ALK Inhibitors in ALK+ NSCLC		
	Moderator:		Dr Ullas Batra Senior Consultant, Medical Oncology Chief of Thoracic Medical Services Rajiv Gandhi Cancer Institute and Research Centre, Delhi

Panelists:

Dr Deepak Koppaka
Senior Consultant Medical Oncologist
Care Hospitals, Hyderabad

Dr Rajat Bajaj
Senior Consultant, Medical Oncology
Fortis Hospital, Noida

Dr Sameer Shrigangwar
Consultant, Medical Oncology
National Cancer Institute, Nagpur

Dr Kumar Prabhash
Prof. & Head- Department of Medical Oncology
Tata Memorial Hospital Parel, Mumbai



Time	Topic	Objective	Speaker
------	-------	-----------	---------

Session Sponsored By:  **NOVARTIS**
Reimagining Medicine

07:15-07:35PM	Capmatinib: The Unmet Need In MET Ex14 Skipping Mutated NSCLC		TBC
---------------	--	--	-----

Session Sponsored By: 

wALK The Frontline in ALK NSCLC

Moderator

Dr Ullas Batra
Senior Consultant, Medical Oncology
Chief of Thoracic Medical Services
Rajiv Gandhi Cancer Institute and Research Centre
Delhi

Panelists

Dr Akhil Kapoor
Assistant Professor,
Medical Oncology
Tata Memorial Hospital
(HBCH & MPMMCC), Varanasi

Dr Ajay Kumar Singh
Consultant Medical Oncologist
Tata Memorial Centre, Mumbai

Dr Ram Abhinav
Consultant Medical Oncologist
Kovai Medical Center and Hospital in
Peelamedu, Coimbatore

Session Sponsored By: 

08:00-08:30PM	Cyramza Clinical Evidence In Second Line Lung Cancer		Dr Kumar Prabhash, Prof. & Head- Department of Medical Oncology Tata Memorial Hospital Parel, Mumbai
---------------	---	--	---

08:30PM Onwards	Closing Remarks		
-----------------	-----------------	--	--



Day 3- 24th July
10:00-02:00pm

Time	Topic	Objective	Speaker
10:00-10:05AM	Welcome & Introduction		Dr Vijay Patil Professor (Medical Oncology) Solid Tumor, Tata Memorial Centre, Mumbai
10:05-10:15AM	LD SCLC- Radiation	Selection Of Case, Time, . Dose , Fractionation, Volumes, Results- Efficacy, Adverse Events	Dr Ritika Harjani Junior Consultant · P. D. Hinduja National Hospital & Medical Research Centre, Mumbai
10:15-10:25AM	LD SCLC- Concurrent Chemotherapy	Regimen, Schedule, Adverse Event And Compliance, Efficacy	Dr Nikhil Pande Consultant Medical Oncologist American Oncology Institute Hinga, Nagpur
10:25-10:35AM	LD SCLC- Neoadjuvant	Selection Of Case, Regimen, Schedule, Adverse Event And Compliance, Efficacy	Dr. Shruti Kate Consultant & Head Medical Oncology HCG Manavata Cancer Centre, Nashik
10:35-10:45AM	ED- Selection Of First Line Chemotherapy	Regimen, Schedule, Adverse Event And Compliance, Efficacy	Dr Avinash Talele Consultant, Medical Oncologist Restora Onco Care, Apollo Hospital, Mumbai
10:45-10:55AM	Selection Of Regimen- Poor PS & SVCO	Regimen, Response, Checking TLS	Dr Gautam Goyal Senior Consultant Medical & Oncologist , Max Hospital, Mohali

Session Sponsored By:



10:55-11:05AM	ED- SCLC - Selection of immunotherapy	First Line, Maintainance, Second Line	Dr Amol Dongre Sr. Consultant - Medical Oncology, Alexis Multispeciality Hospital, Nagpur
11:05-11:15AM	ED- Selection Of The Second Line And Beyond	Regimen, Schedule, Adverse Event And Compliance, Efficacy	Dr Tanmoy Kumar Mandal Consultant Medical and Hemato Oncologist, AMRI Hospital Dhakuria, Kolkata



Time	Topic	Objective	Speaker
KRAS			
Session Sponsored By: 			
11:15-11:30AM	Interpretation Of KRAS Mutation	FISH, IHC ,NGS	Dr Prashanth Bagali Practice Head- Oncology Strand Lifesciences, Bangalore
11:30-11:40AM	Selection Of 1st Line Therapy For KRAS	Agents, Efficacy, Side Effects And Tips For Selection	Dr Amit Kumar Senior Consultant, Medical Oncology and Hemato- oncology, Medanta Hospital, Patna
11:40-11:50AM	Mechanism Of Resistance To KRAS TKI And Therapy Post Resistance	Agents, Efficacy, Side Effects And Tips For Selection	Dr. Pritam Kataria Deputy Consultant Dept. of Medical Oncology Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai
BRAF			
11:50-12:00PM	Evaluation Of BRAF Mutation Testing Methodology: Technologies & Their Interpretation	FISH, IHC ,NGS	Dr Firoz Ahmad Section Head- Molecular Pathology SRL Diagnostics, Mumbai
12:00-12:15PM	Selection Of 1st Line Targeted Therapy For BRAF Mutated NSCLC	Agents, Efficacy, Side Effects And Tips For Selection	Dr Ullas Batra Senior Consultant, Medical Oncology Chief of Thoracic Medical Services Rajiv Gandhi Cancer Institute and Research Centre, Delhi
12:15-12:25PM	Mechanism Of Resistance To BRAF TKI And Therapy Post Resistance In BRAF Mutated NSCLC	Agents, Efficacy, Side Effects And Tips For Selection	Dr. Rakesh Pinninti Consultant Medical Oncologist, Basavatarakam Hospital, Hyderabad
NTRK			
12:25-12:40PM	Interpretation Of NTRK Mutation	FISH, IHC ,NGS	Dr. Jay Mehta Surgical Anatomic & Molecular Pathologist, Tata Trusts Mumbai
12:40-12:50PM	Selection Of 1st Line Therapy For NTRK	Agents, Efficacy, Side Effects And Tips For Selection	Dr. Ashish Singh MD, DM (Medical Oncology) Professor, Dept. of Medical Oncology Christian Medical College Vellore



Time	Topic	Objective	Speaker
12:50-01:00PM	Mechanism Of Resistance To NTRK TKI And Therapy Post Resistance	Agents, Efficacy, Side Effects And Tips For Selection	Dr Vikas Talreja Consultant, Department of Medical Oncology, Regency Hospital, Kanpur
RET			
01:00-01:10PM	Interpretation Of RET Mutation	FISH, IHC ,NGS	Dr Trupti Pai Associate Professor & Consultant Pathologist Tata Memorial Hospital, Mumbai
01:10-01:20PM	Selection Of 1st Line Therapy For RET	Agents, Efficacy, Side Effects And Tips For Selection	Dr Bhavesh Poladia Consultant Medical Oncologist, Thangam Hospital and Thangam Cancer Center, Namakkal, Tamilnadu
01:20-01:30PM	Mechanism Of Resistance To RET TKI And Therapy Post Resistance	Agents, Efficacy, Side Effects And Tips For Selection	Dr Akhil Kapoor Assistant Professor, Medical Oncology Tata Memorial Hospital (HBCH & MPMMCC), Varanasi
Exon 20			
01:30-01:40PM	Interpretation Of Exon 20 Insertion	FISH, IHC ,NGS	Dr. Omshree Shetty Assistant Professor and Scientific Office Tata Memorial Hospital, Mumbai
01:40-01:50 PM	Selection Of 1st Line Therapy For EXON 20 Insertion	Agents, Efficacy, Side Effects And Tips For Selection	Dr. Arun Chandrasekharan Senior Medical Oncologist Aster MIMS, Calicut
01:50-02:00PM	Mechanism Of Resistance To EXON 20 Insertion TKI And Therapy Post Resistance	Agents, Efficacy, Side Effects And Tips For Selection	Dr. Mounika Boppana Consultant Medical Oncologist, Krishna Institute of Medical Sciences (KIMS), Secunderabad, Hyderabad
02:05PM Onwards	Closing Remarks		



Academic Partners



Lilly



INTAS
ONCOLOGY



AstraZeneca



MSD
INVENTING FOR LIFE



Pfizer



NOVARTIS
Reimagining Medicine



Roche



Cipla
ONCOLOGY
Pioneering Cancer Care | Embracing Lives



strand
New Generation Healthcare



Emcure[®]
SUCCESS THROUGH INNOVATION



4baseCare
Together We Beat Cancer



NATCO
ONCOLOGY



MB
MEDICAMEN



INTAS
ONCOLOGY



glenmark
oncology
It's Our Commitment



Dr.Reddy's
Good Health Can't Wait.



zydus
Dedicated To Life



SUN
ONCOLOGY
a SUN PHARMA division



Thank You



CONTACT US :
GARIMA VASISTH
+91 8178985238



Event Managed By:
Horizon Conference
Management Pvt. Ltd.



contact@cancerresearchfoundation.in